SCARB1 and cancer: These drug containing rHDL nanoparticles provide a targeted delivery vehicle with broad therapeutic potential due to the limited expression of the SR-B1 in normal tissue and the over-expression of this receptor by the vast majority of cancer types (Shahzad et al., 2011).